Results of the 17 included studies investigating FDG-PET
| HD/NHL; Study, year . | Scoring system . | Initial staging . | Restaging . | ||
|---|---|---|---|---|---|
| Sensitivity, % (95% CI) . | Specificity, % (95% CI) . | Sensitivity, % (95% CI) . | Specificity, % (95% CI) . | ||
| HD | |||||
| Meany et al,41 2007 | Patient-based analysis | — | — | 100 (34.2-100) | 57.1 (36.6-75.5) |
| Bjurberg et al,42 2006 | Patient-based analysis | — | — | 91.7 (64.6-98.5) | 95.2 (77.3-99.2) |
| Zinzani et al,43 2006 | Patient-based analysis | — | — | 87.5 (52.9-97.8) | 100 (89.0-100) |
| Rigacci et al,38 2005 | Patient-based analysis | — | — | 100 (51.0-100) | 83.3 (64.2-93.3) |
| Filmont et al,44 2004 | Patient-based analysis | — | — | 100 (74.1-100) | 85.7 (65.4-95.0) |
| Mikosch et al,50 2003 | Patient-based analysis | — | — | 100 (87.1-100) | 81.8 (65.6-91.4) |
| Dittmann et al,45 2001 | Patient-based analysis | — | — | 86.2 (69.4-94.5) | 94.4 (74.2-99.0) |
| Mikhaeel et al,51 2000 | Patient-based analysis | — | — | 100 (43.9-100) | 91.7 (64.6-98.5) |
| Stumpe et al,54 1998 | Lesion-based analysis | 87.5 (52.9-97.8) | 100 (34.2-100) | 85.0 (64.0-94.8) | 95.7 (79.0-99.2) |
| NHL | |||||
| Mikosch et al,50 2003* | Patient-based analysis | — | — | 81.5 (63.3-91.8) | 80.0 (64.1-90.0) |
| Filmont et al,46 2003† | Patient-based analysis | — | — | 87.0 (74.3-93.9) | 93.8 (79.9-98.3) |
| Mikhaeel et al,47 2000‡ | Patient-based analysis | — | — | 60.0 (35.8-80.2) | 100 (88.7-100) |
| Mikhaeel et al,51 2000§ | Patient-based analysis | — | — | 71.4 (35.9-91.8) | 100 (72.3-100) |
| Stumpe et al,54 1998¶ | Lesion-based analysis | 83.3 (43.7-97.0) | 100 (20.7-100) | 100 (43.9-100) | 100 (67.6-100) |
| Mixed | |||||
| La Fougere et al,39 2006 | Region-based analysis (7 predefined regions) | 97.9 (89.1-99.6) ‖; 100 (87.5-100)† | 98.1 (93.4-99.5) ‖; 100 (93.7-100) † | 96.4 (82.3-99.4) ‖; 97.3 (90.8-99.3) † | 99.4 (96.7-99.9) ‖; 98.4 (95.5-99.5) † |
| Hernandez-Pampaloni et al,40 2006 | Patient-based analysis | — | — | 100 (51.0-100) | 88.2 (65.7-96.7) |
| Reinhardt et al,48 2005 | Patient-based analysis | — | — | 71.4 (52.9-84.8) | 94.5 (86.7-97.9) |
| Freudenberg et al,48 2004 | Region-based analysis (5 predefined regions); | — | — | 78.3 (58.1-90.3) | 98.2 (93.7-99.5) |
| Freudenberg et al,48 2004 | Patient-based analysis | — | — | 85.7 (60.1-96.0) | 100 (77.2-100) |
| Bangerter et al,52 1999 | Patient-based analysis | — | — | 71.4 (35.9-91.8) | 86.2 (69.4-94.5) |
| Bangerter et al,53 1999 | Patient-based analysis | — | — | 85.7 (48.7-97.4) | 96.1 (86.8-98.9) |
| HD/NHL; Study, year . | Scoring system . | Initial staging . | Restaging . | ||
|---|---|---|---|---|---|
| Sensitivity, % (95% CI) . | Specificity, % (95% CI) . | Sensitivity, % (95% CI) . | Specificity, % (95% CI) . | ||
| HD | |||||
| Meany et al,41 2007 | Patient-based analysis | — | — | 100 (34.2-100) | 57.1 (36.6-75.5) |
| Bjurberg et al,42 2006 | Patient-based analysis | — | — | 91.7 (64.6-98.5) | 95.2 (77.3-99.2) |
| Zinzani et al,43 2006 | Patient-based analysis | — | — | 87.5 (52.9-97.8) | 100 (89.0-100) |
| Rigacci et al,38 2005 | Patient-based analysis | — | — | 100 (51.0-100) | 83.3 (64.2-93.3) |
| Filmont et al,44 2004 | Patient-based analysis | — | — | 100 (74.1-100) | 85.7 (65.4-95.0) |
| Mikosch et al,50 2003 | Patient-based analysis | — | — | 100 (87.1-100) | 81.8 (65.6-91.4) |
| Dittmann et al,45 2001 | Patient-based analysis | — | — | 86.2 (69.4-94.5) | 94.4 (74.2-99.0) |
| Mikhaeel et al,51 2000 | Patient-based analysis | — | — | 100 (43.9-100) | 91.7 (64.6-98.5) |
| Stumpe et al,54 1998 | Lesion-based analysis | 87.5 (52.9-97.8) | 100 (34.2-100) | 85.0 (64.0-94.8) | 95.7 (79.0-99.2) |
| NHL | |||||
| Mikosch et al,50 2003* | Patient-based analysis | — | — | 81.5 (63.3-91.8) | 80.0 (64.1-90.0) |
| Filmont et al,46 2003† | Patient-based analysis | — | — | 87.0 (74.3-93.9) | 93.8 (79.9-98.3) |
| Mikhaeel et al,47 2000‡ | Patient-based analysis | — | — | 60.0 (35.8-80.2) | 100 (88.7-100) |
| Mikhaeel et al,51 2000§ | Patient-based analysis | — | — | 71.4 (35.9-91.8) | 100 (72.3-100) |
| Stumpe et al,54 1998¶ | Lesion-based analysis | 83.3 (43.7-97.0) | 100 (20.7-100) | 100 (43.9-100) | 100 (67.6-100) |
| Mixed | |||||
| La Fougere et al,39 2006 | Region-based analysis (7 predefined regions) | 97.9 (89.1-99.6) ‖; 100 (87.5-100)† | 98.1 (93.4-99.5) ‖; 100 (93.7-100) † | 96.4 (82.3-99.4) ‖; 97.3 (90.8-99.3) † | 99.4 (96.7-99.9) ‖; 98.4 (95.5-99.5) † |
| Hernandez-Pampaloni et al,40 2006 | Patient-based analysis | — | — | 100 (51.0-100) | 88.2 (65.7-96.7) |
| Reinhardt et al,48 2005 | Patient-based analysis | — | — | 71.4 (52.9-84.8) | 94.5 (86.7-97.9) |
| Freudenberg et al,48 2004 | Region-based analysis (5 predefined regions); | — | — | 78.3 (58.1-90.3) | 98.2 (93.7-99.5) |
| Freudenberg et al,48 2004 | Patient-based analysis | — | — | 85.7 (60.1-96.0) | 100 (77.2-100) |
| Bangerter et al,52 1999 | Patient-based analysis | — | — | 71.4 (35.9-91.8) | 86.2 (69.4-94.5) |
| Bangerter et al,53 1999 | Patient-based analysis | — | — | 85.7 (48.7-97.4) | 96.1 (86.8-98.9) |
— indicates no entry.
*Histologic subtype(s) of NHL not described.
† High-grade NHL in 51 patients, low-grade NHL in 11 patients, and unknown histologic grade in 16 patients.
‡All patients had aggressive NHL (diffuse mixed, diffuse large-cell, or large-cell immunoblastic lymphoma).
§Aggressive histology NHL (diffuse mixed, diffuse large-cell, and large-cell immunoblastic lymphoma).
¶Nine with high-grade and 6 with low-grade NHL.
‖ Dedicated PET-scanner.
†FDG-PET portion of a combined FDG-PET/CT examination.